Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 248 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High dose formulation Clear all
Completed Phase 1 Interventional

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT02167958
View directory record Official record
Conditions
Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
Drug · Radiation · Other
Lead sponsor
Rafic Farah, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 19, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

NCT06493578
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
VYN201 Gel, Vehicle Gel
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 3 Interventional Results available

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

NCT01545076
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Interventions
IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT05050318
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

NCT01091649
View directory record Official record
Conditions
Healthy
Interventions
ABT-450, ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 in Healthy Subjects

NCT01450098
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2484595 Reference Formulation (RF), LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 19, 2026, 11:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

NCT05456425
View directory record Official record
Conditions
Pterygium
Interventions
CBT-001, Vehicle
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

NCT02927873
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 23 Months
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
6
States / cities
Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Obesity, Oral Contraception, and Ovarian Suppression

NCT00827632
View directory record Official record
Conditions
Ovarian Suppression
Interventions
Low dose formulation, High dose formulation
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 19, 2026, 11:50 PM EDT
Not listed Not applicable Interventional

High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

NCT00247143
View directory record Official record
Conditions
HIV, AIDS
Interventions
Kaletra (drug)
Drug
Lead sponsor
Lampiris, Harry W., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2006 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Results available

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

NCT02742103
View directory record Official record
Conditions
Acute Myocardial Infarction, Moderate Renal Impairment
Interventions
CSL_112, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)

NCT06619314
View directory record Official record
Conditions
Healthy
Interventions
Calderasib, PPI
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

NCT01946438
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

NCT01500434
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
21
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 19, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

CHI-907 CBD Extract and Experiences of Test Anxiety

NCT04269252
View directory record Official record
Conditions
Anxiety
Interventions
CHI-907, CHI-804
Other
Lead sponsor
Canopy Growth Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Harrisonburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

NCT01430819
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Colorado Springs, Colorado • Council Buffs, Iowa • Metairie, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

NCT03555617
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
TD-1473, Itraconazole
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

NCT02321644
View directory record Official record
Conditions
Healthy Subjects
Interventions
CC-90001
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Daytona Beach, Florida • Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

NCT02509104
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 50 Years
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
12
States / cities
Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

NCT05664334
View directory record Official record
Conditions
Healthy
Interventions
IVX-121, IVX-241, Placebo, MF59®
Biological · Other
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

NCT05319899
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 1 Interventional

A Study of Tor Kinase Inhibitor in Advanced Tumors

NCT00731263
View directory record Official record
Conditions
Solid Tumors
Interventions
AZD8055
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 19, 2026, 11:50 PM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 19, 2026, 11:50 PM EDT